Single nucleotide polymorphism in ERCC1 118C→T predicts the outcome of NSCLC patients receiving platinum-based chemotherapy

Objective:ERCC1 is emerging as essential elements in repairing platimun-DNA adducts.The aim of this study is to investigate whether the single nucleotide polymorphism(SNP) in Excision repair cross-complementation group 1(ERCC1) 118C→T is associated with the clinical prognosis of platinum-based chemotherapy in non-small-cell lung cancer.Methods: SNP of ERCC1 118C→T was genotyped by PCR-restrictive fragment length polymorphism(PCR-RFLP).The pathological parameters and survival data were evaluated according to the different genotypes in 47 NSCLC patients.Results: ERCC1 118C→T was not related to clinic pathological parameters in NSCLC(P0.05).The median survival of patients with C/C genotypes was 25.0 months compared to 10.5 months of C/T or T/T genotypes(P=0.012).In Cox regresssion models,ERCC1 118C→T was significantly associated with overall survival time of NSCLC patients(P=0.015).Conclusion: ERCC1 codon118 SNP might be a predictive marker of survival for NSCLC patients receiving platinum-based chemotherapy.